Bayer Archives

News and Trends 22 Sep 2016

Evotec and Bayer renew their vows and take on Kidney Disease

Evotec and Bayer are approaching the 4th anniversary of a successful partnership in endometriosis treatments that made it to clinical trials just last month. To celebrate, they’re starting a new 5-year partnership, this time concerning kidney disease. Evotec has a long list of top-level partners, including Roche, Sanofi, Boehringer Ingelheim and Takeda. After the successful outcome of […]

September 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Aug 2016

€350M CRISPR Joint Venture now has a Name and an Office

Bayer and CRISPR Therapeutics have invested $373M in a joint venture, Casebia, as the latest effort to bring the revolutionary gene editing technology to the medical market. This brainchild represents a huge leap of faith, since no preliminary results have been revealed. The Boston launch may accelerate its progress through clinical trials and produce the first […]

August 23, 2016 - 3 minutesmins - By Evelyn Warner

endometriosis treatment womens health biotech

News and Trends 8 Aug 2016

A €580M Collaboration for Endometriosis Therapies breaks into Clinical Development

Update (24/07/2017): Bayer and Evotec have announced a second compound from their partnership made it to clinical trials in humans. Consequently, they have decided to extend the partnership for an extra year and develop 4 candidates instead of the original 3. Originally published on 08/08/2016 An endometriosis therapy is now moving to clinical development. It’s […]

August 8, 2016 - 3 minutesmins - By Denise Neves Gameiro

crispr charpentier ers genomics bayer blsc

News and Trends 18 May 2016

Bayer claims CRISPR Patents for Gene-Editing Agreements

Bayer has signed a patent license agreement with ERS Genomics, that controls patents for the CRISPR-Cas9 system – a breakthrough gene-editing technology. Bayer Lifescience Center (BLSC) is the innovation division of German Giant Bayer, which aims to address challenges in the pharmaceutical and agro-industry. Its strategy is to establish collaborations with innovative Biotechs, and create a […]

May 18, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 11 May 2016

German mRNA specialist moves into Animal Health in collaboration with Bayer

BioNTech is joining its mRNA technology with Bayer’s expertise in veterinary applications in a new collaboration – to develop first-in-class vaccines for animals. Based in Mainz (Germany), BioNTech is the largest private Biotech in Europe. Along with its CAR-T and TCR programmes, BioNTech is developing mRNA therapies – a promising field in medicine. These include immunotherapies for […]

May 11, 2016 - 2 minutesmins - By Denise Neves Gameiro

spix meiogenix bayer crop gene technology crispr food meiotic spo11 recombination biotech agriculture

News and Trends 8 Apr 2016

French Gene Technology and Bayer to ‘Unlock’ Food Crop Diversity

Meiogenix (France) has signed with Bayer Crop Science (Germany) for use of their gene-editing platform, to try and ‘Unlock’ crop genetic diversity and improve food security. Launched in 2011, this Parisian biotech was a spin-off of the Institut Curie and the French Agricultural Agency (INRA) after successfully raised funding. Now, under this non-exclusive agreement, Meiogenix […]

April 8, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 24 Feb 2016

German Biotech wins FDA Approval for New Liver Cancer Trial

4SC, in Germany, has the FDA’s green light to conduct efficacy trials in the US with a candidate drug against hepatocellular carcinoma. Munich-based 4SC’s lead candidate, resminostat, is a small-molecule being tested in several trials for some of the deadliest cancers. These include liver – which is also known as hepatocellular carcinoma (HCC). Resminostat is an inhibitor of histone […]

February 24, 2016 - 3 minutesmins - By Denise Neves Gameiro

crispr bayer therapeutics genetic disease joint venture london

News and Trends 22 Dec 2015

Serious Genetic Diseases have a New CRISPR Dream Duo Venture worth in Excess of €275M

Blood disorders, blindness and congenital heart disease? The new Bayer Life Science Center (BLSC) in Germany and CRISPR Therapeutics (Switzerland) have now created a joint Venture to tackle cures for these rare genetic defects. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise […]

December 22, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 30 Jul 2015

NASDAQ-listed Sprint Bioscience sells early-stage Cancer Treatment to Bayer

Just as Boehringer Ingelheim, Bayer HealthCare expands its cancer portfolio this week. The German company is inclined to shell out €190M for a drug that interacts with the peculiar metabolism of cancer cells. Its developer, Sprint Bioscience AB, is a Swedish company founded in 2009, from former members of AstraZeneca, Biovitrum, and Pharmacia. Sprint Bioscience is a […]

July 30, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 16 Apr 2015

Bayer Healthcare invests €94 Million in its Hemophilia pipeline

Bayer HealthCare, a subgroup of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry. Yesterday, the company announced a €94M investment in its Berkeley (California) manufacturing site to build a product testing facility that will support the next generation of treatments for patients with hemophilia A. David […]

April 16, 2015 - 2 minutesmins - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us